Entos Pharmaceuticals announces selection of lead DNA vaccine candidates for COVID-19

(Entos Pharmaceuticals) In preclinical studies, two lead Fusogenix DNA vaccine (Covigenix) candidates demonstrated high immunogenicity and efficacy.Lead candidates to be evaluated in SARS-CoV-2 animal challenge studies and advanced to human clinical trials during summer 2020.Canadian Institutes of Health Research (CIHR) awards $4.2M grant to John Lewis, PhD., to be used for development of COVID-19 DNA vaccine.
Source: EurekAlert! - Biology - Category: Biology Source Type: news